Bryan, Garnier & Co part of bulge bracket syndicate for DBV $150 million Follow-on

Bryan, Garnier & Co part of bulge bracket syndicate for DBV $150 million Follow-on

News published on March Thursday 22, 2018
Share on

Context

DBV Technologies dual listed on Nasdaq since October 2014.

PEPITES phase III results released in October 2017 showed a 35.5% responder rate vs. 13.6% for the placebo at a 250ug dose (p=0.00001) with a strong safety profile.

FDA filing for Viaskin Peanut expected in 2018 H2.

Viaskin Milk phase 2 results released in February 2018 validated further the EPIT platform.

Equity raise to fund the development and commercialization of Viaskin Peanut and to advance development of other product candidates.

Transaction highlights

Continued support of Bryan, Garnier & Co alongside a syndicate made up of bulge brackets Morgan Stanley, Goldman Sachs, Barclays and Deutsche Bank.

Previously we accompanied DBV in its NASDAQ IPO in October 2014 and in its two subsequent NASDAQ follow-ons.

Gross proceeds of $150 million (€122.5 million) on the back of substantial demand.

Price of €34.71 per ordinary share at a discount of 4.99% to the 3-day VWAP.

61% of the issue in the form of ordinary shares and 39% in the form of ADSs.

Transaction anchored by Baker Bros Advisors for $47.4 million and Bpifrance for $24.9 million.

5th healthcare transaction announced by Bryan, Garnier & Co in 2018 .

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY.

(www.dbv-technologies.com)

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Zurich and New York. The firm is a member of the London Stock Exchange and Euronext.

(www.bryangarnier.com)

Deal team

Hervé Ronin
Partner
T: +33 1 70 36 57 22

Dr Anne Moore
Vice President
T: +33 1 56 68 75 39

Cosme Rosellini
Vice President
T: +33 1 56 68 75 28

Jean de Pracomtal
Vice President
T: +33 1 56 68 75 38


The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities